Quincy Bioscience, a research-based biotechnology company, presented data demonstrating an apoaequorin-containing supplement is able to significantly improve cognitive function for adults with memory concerns. The trial findings were shared at the annual Alzheimer’s Association Int’l. Conference (AAIC) in Paris held in July 2011.

Quincy Bioscience President Mark Underwood presented the results of the Madison Memory Study to the world’s leading Alzheimer’s disease researchers interested in effective treatments for the growing global problem of age-related cognitive decline and forms of dementia, such as Alzheimer’s disease. "The Madison Memory Study is significant because the results, which were obtained through computer-based assessments of memory, suggest daily use of apoaequorin is helpful for improving cognitive function in adults who are experiencing some memory impairment," said Underwood.

 

Key findings presented:

The double blind, placebo-controlled study of 218 adults demonstrated apoaequorin was able to significantly improve executive function, word recall, and short-term memory compared to placebo over 90 days.

The apoaequorin arm was able to reduce the total number of errors in a measure of cognitive function by 19 percent compared to baseline and significantly fewer errors than placebo.

In a task requiring participants to learn a grocery shopping list, the apoaequorin group was able to recall significantly more items at Day 90 compared to baseline.

 

Apoaequorin is a calcium-binding protein derived from a species of jellyfish and has demonstrated neuroprotective properties by buffering excessive levels of intracellular calcium in brain cells. "The Alzheimer’s research community has known for some time that unregulated calcium is a culprit," explains Underwood. "There haven’t been any compounds to address this cause. These results are very promising and demonstrate that apoaequorin can help people with memory concerns. Our next step is a larger scale study specifically targeting the Alzheimer’s population." Parties interested in reviewing the research can visit http://quincybioscience.com/effects-of-apoaequorin/.

 

About AAIC

The Alzheimer's Association Int’l. Conference is the world's premiere forum for reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders.

 

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, WI, focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

Quincy has developed products for the dietary supplement marketplace under the brand Prevagen®. First launched in September 2007, Prevagen® has helped thousands of people with cognitive difficulties.

President and a Founder of Quincy Bioscience, Mark Underwood lives in Madison, WI with his wife and their two daughters. Prior to forming Quincy Bioscience, Underwood was an executive in the contract manufacturing industry and heavily involved in product development for retail product brands. He has an academic background in neurochemistry and is the inventor of the technology within Quincy Bioscience.